Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Seven patients with uterine
endometrial carcinoma
received a postoperative combination chemotherapy with ifosfamide (1g/m2) daily for 5 days, and adriamycin (50mg/m2) and cisplatin (50mg/m2) on day 1 (
IAP
). All except one patient with the disease without myometrial invasion received 5 courses or more of
IAP
treatment. Of four patients with measurable disease, three achieved complete response (CR) and the other patient obtained partial response (PR), indicating a 100% response rate. In the PR case, the patient had previously been treated by radiation treatment for cervical cancer, and the histology of the tumor was papillary serous adenocarcinoma, a malignant variant of
endometrial cancer
. Six patients underwent second look operation following the planned
IAP
treatment courses, and the operation confirmed no pathological evidence of disease in any, although in one disease recurred 7 months after the second laparotomy. Side effects were remarkable, including an 87% incidence of grade 4 leucopenia. However, the patients recovered spontaneously from the hematologic toxicity within 3 weeks of treatment. Other toxic effects including central nervous system toxicity were controllable and acceptable. The results indicated that
IAP
combination therapy was feasible and promising in the management of patients with
endometrial carcinoma
.
...
PMID:A preliminary study of a combination chemotherapy with ifosfamide, adriamycin and cisplatin for endometrial carcinoma. 320 14
The changes in serum CA125, CA19-9, CEA, Ferritin, TPA,
IAP
and LDH concentrations were measured in 22 primary cases and 7 recurrent cases of adenocarcinoma of the uterine cervix and
endometrial carcinoma
in order to examine the clinical usefullness of CA125 and CA19-9 as a tumor marker. Localization of CA125 and CA19-9 was also examined in adenocarcinoma, normal endocervix and endometrium immunohistochemically. 1. Twenty-seven percent of primary cases had increased serum CA125 and CA19-9 which decreased rapidly after operation or chemotherapy, reflecting reduction of the tumor mass. 2. In these cases, CA125 or CA19-9 was localized in carcinoma tissues immunohistochemically. On the other hand, in normal endocervical and endometrial glands, CA125 was localized, but CA19-9 was not. 3. In most recurrent cases, serum CA125 and CA19-9 increased early and markedly, compared with the other markers. 4. The change in serum Ferritin, CEA, TPA,
IAP
and LDH didn't reflect clinical courses such as operation and chemotherapy. In recurrent cases they increased even more slowly and slightly than CA125 or CA19-9. These results show that CA125 and CA19-9 are useful tumor markers in the management of adenocarcinoma of the uterine cervix and
endometrial carcinoma
, especially in advanced or recurrent cases.
...
PMID:[Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma]. 323 84
Prostate cancer (PCa) is one of the major leading cause in men and no effective biomarkers or therapy have been approved for it to date. This study aimed to explore the molecular mechanisms and identify the potential molecular biomarkers of PCa. The microarray profile GSE38241 including 18 prostate cancer metastasis and 21 normal prostate samples was retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified by Limma. DEGs functions were investigated by Gene Ontology (GO) and pathway enrichment analysis. Moreover, protein-protein interaction (PPI) network of DEGs was constructed, followed by functional analysis of modules. Additionally, pathway crosstalk network was constructed by integrating PPI network and Kyoto encyclopedia of genes and genomes (KEGG) pathways. Totally, 334 up - and 703 down-regulated DEGs were identified. The functions of up-regulated DEGs were significantly enriched in GO terms of cell cycle phase and cell cycle process. While down-regulated DEGs mainly participated in actin filament-based process. Among these pathways in the pathway crosstalk network, T cell receptor signaling pathway, chemokine signaling pathways,
endometrial cancer
and glioma were found to play critical roles during PC progression. Cell division cycle 45 (CDC45), baculoviral
IAP
repeat containing 5 (BIRC5) and cell division cycle associated 5 (CDCA5) may be useful markers for predicting tumor metastasis and therapeutic targets for the treatment of PCa patients. Moreover, the pathway crosstalk network provides the groundwork that targeting multiple pathways might be more effective than targeting one pathway alone.
...
PMID:Pathway crosstalk analysis in prostate cancer based on protein-protein network data. 2788 Oct 1